ZA200504613B - Solid drug for oral use - Google Patents
Solid drug for oral use Download PDFInfo
- Publication number
- ZA200504613B ZA200504613B ZA200504613A ZA200504613A ZA200504613B ZA 200504613 B ZA200504613 B ZA 200504613B ZA 200504613 A ZA200504613 A ZA 200504613A ZA 200504613 A ZA200504613 A ZA 200504613A ZA 200504613 B ZA200504613 B ZA 200504613B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical according
- pharmaceutical
- dissolution
- test
- agent
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims description 37
- 239000003814 drug Substances 0.000 title description 30
- 229940079593 drug Drugs 0.000 title description 3
- 238000004090 dissolution Methods 0.000 claims description 70
- 239000002775 capsule Substances 0.000 claims description 69
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 50
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 35
- 239000004480 active ingredient Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000000314 lubricant Substances 0.000 claims description 29
- 206010013990 dysuria Diseases 0.000 claims description 28
- 235000019359 magnesium stearate Nutrition 0.000 claims description 27
- 239000006186 oral dosage form Substances 0.000 claims description 27
- 238000007922 dissolution test Methods 0.000 claims description 26
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 25
- -1 indoline compound Chemical class 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000945 filler Substances 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 14
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 210000003708 urethra Anatomy 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000002981 blocking agent Substances 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 7
- 239000000812 cholinergic antagonist Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 230000027939 micturition Effects 0.000 claims description 5
- 206010020880 Hypertrophy Diseases 0.000 claims description 4
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 4
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 208000026723 Urinary tract disease Diseases 0.000 claims description 3
- 208000014001 urinary system disease Diseases 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 86
- 238000009472 formulation Methods 0.000 description 75
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 37
- 238000002156 mixing Methods 0.000 description 30
- 229960005196 titanium dioxide Drugs 0.000 description 28
- 239000003826 tablet Substances 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
- 239000000654 additive Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000008187 granular material Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 239000012085 test solution Substances 0.000 description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000012086 standard solution Substances 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 6
- 238000005286 illumination Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229920001451 polypropylene glycol Polymers 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000001782 photodegradation Methods 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 235000010215 titanium dioxide Nutrition 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000013507 chronic prostatitis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000005429 filling process Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 150000002476 indolines Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000015824 Fowler syndrome Diseases 0.000 description 1
- 208000035381 Fowler urethral sphincter dysfunction syndrome Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000026602 Hinman syndrome Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036968 Prostatic pain Diseases 0.000 description 1
- 206010037195 Psychogenic dysuria Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 description 1
- 229960003103 alfuzosin hydrochloride Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960002386 prazosin hydrochloride Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000018591 proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome Diseases 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002364238 | 2002-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504613B true ZA200504613B (en) | 2006-08-30 |
Family
ID=32588229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504613A ZA200504613B (en) | 2002-12-16 | 2005-06-06 | Solid drug for oral use |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20060018959A1 (pl) |
| EP (2) | EP1574215B1 (pl) |
| JP (1) | JP4633469B2 (pl) |
| KR (2) | KR101072909B1 (pl) |
| CN (2) | CN101069685B (pl) |
| AU (1) | AU2003289320C1 (pl) |
| BR (1) | BR0317349A (pl) |
| CA (1) | CA2507002C (pl) |
| EA (1) | EA008196B1 (pl) |
| ES (1) | ES2544560T3 (pl) |
| HK (2) | HK1085131A1 (pl) |
| HR (1) | HRP20050544B1 (pl) |
| IL (1) | IL169040A (pl) |
| IS (1) | IS7929A (pl) |
| ME (2) | MEP10808A (pl) |
| MX (1) | MXPA05006513A (pl) |
| NO (1) | NO20053467L (pl) |
| NZ (1) | NZ540664A (pl) |
| PL (1) | PL220457B1 (pl) |
| RS (1) | RS58025B1 (pl) |
| TW (2) | TWI325318B (pl) |
| UA (2) | UA85359C2 (pl) |
| WO (1) | WO2004054574A1 (pl) |
| ZA (1) | ZA200504613B (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070003968A (ko) * | 2004-03-05 | 2007-01-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 신경 장애에 따른 과활동 방광의 예방 또는 치료용 의약조성물 |
| WO2006038611A1 (ja) * | 2004-10-05 | 2006-04-13 | Kissei Pharmaceutical Co., Ltd. | 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤 |
| MX2009009230A (es) * | 2007-02-28 | 2009-11-26 | Kissei Pharmaceutical | Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna. |
| WO2008114800A2 (en) * | 2007-03-13 | 2008-09-25 | Takeda Pharmaceutical Company Limited | Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile |
| JP5965902B2 (ja) | 2010-06-28 | 2016-08-10 | ラティオファルム ゲー・エム・ベー・ハー | シロドシン−シクロデキストリン包接化合物 |
| WO2012010669A2 (de) | 2010-07-23 | 2012-01-26 | Ratiopharm Gmbh | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer |
| EP2474529B1 (en) | 2010-12-23 | 2014-05-14 | Sandoz AG | Crystalline forms of an active pharmaceutical ingredient |
| CN102283816B (zh) * | 2011-08-05 | 2013-09-11 | 北京海步国际医药科技发展有限公司 | 西洛多辛缓释片剂及其制备方法 |
| US20140243383A1 (en) * | 2011-08-24 | 2014-08-28 | Cadila Healthcare Limited | Pharmaceutical compositions of silodosin |
| JP6031722B2 (ja) * | 2011-08-31 | 2016-11-24 | 国立大学法人 千葉大学 | 女性の排尿障害の治療剤 |
| WO2013123419A1 (en) * | 2012-02-16 | 2013-08-22 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| KR102149380B1 (ko) | 2012-07-16 | 2020-08-28 | 피브로겐, 인크. | 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형 |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| JP6392207B2 (ja) | 2013-03-26 | 2018-09-19 | キッセイ薬品工業株式会社 | シロドシンの苦味をマスキングした経口投与製剤 |
| ES2786924T3 (es) | 2013-06-06 | 2020-10-14 | Fibrogen Inc | Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF |
| KR102206104B1 (ko) | 2014-04-03 | 2021-01-22 | 한미약품 주식회사 | 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형 |
| CN103933001A (zh) * | 2014-05-09 | 2014-07-23 | 浙江华海药业股份有限公司 | 一种稳定的赛洛多辛口服固体药物组合物及其制备方法 |
| CN105435233B (zh) * | 2014-08-06 | 2018-05-01 | 江苏正大丰海制药有限公司 | 一种英加韦林的药物组合物 |
| JP6366547B2 (ja) * | 2015-08-03 | 2018-08-01 | 大原薬品工業株式会社 | 光安定性が向上した、プラミペキソール製剤包装体 |
| CN108685867A (zh) * | 2017-04-06 | 2018-10-23 | 昆明积大制药股份有限公司 | 一种赛洛多辛薄膜衣片及其制备方法 |
| EP3354283B1 (en) | 2017-06-20 | 2019-08-07 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical capsule composition comprising silodosin |
| CN111437260A (zh) * | 2019-01-17 | 2020-07-24 | 北京万全德众医药生物技术有限公司 | 用于制备盐酸美金刚固态药物组合物的方法 |
| JP7262005B2 (ja) * | 2019-01-25 | 2023-04-21 | 日本ジェネリック株式会社 | シロドシン含有固形組成物及びその製造法 |
| CN114601826B (zh) * | 2022-03-31 | 2024-06-04 | 乐泰药业有限公司 | 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1060073A (en) | 1963-03-02 | 1967-02-22 | Benger Lab Ltd | 2,2,2-trichlorethyl hydrogen succinate and salts |
| US4547498A (en) | 1983-01-06 | 1985-10-15 | Mylan Pharmaceuticals Inc. | Pharmaceutical combination composition and associated method |
| US4757090A (en) * | 1986-07-14 | 1988-07-12 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
| HU200926B (en) * | 1988-10-28 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules |
| DE69319551T2 (de) | 1992-12-02 | 1998-10-29 | Kissei Pharmaceutical | Indolin Verbindungen zur Behandlung von Dysurien |
| US5370878A (en) * | 1993-09-30 | 1994-12-06 | Hallmark Pharmaceuticals, Inc. | Method for preparing a direct compression granulated acetaminophen composition |
| MX9605419A (es) | 1994-05-06 | 1997-12-31 | Pfizer | Formas de dosificacion de liberacion controlada de azitromicina. |
| ES2125198B1 (es) * | 1997-05-13 | 1999-11-16 | Vita Invest Sa | Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares. |
| AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| WO1999015202A1 (fr) * | 1997-09-22 | 1999-04-01 | Kissei Pharmaceutical Co., Ltd. | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate |
| US20020177593A1 (en) * | 1998-09-30 | 2002-11-28 | Yuji Ishihara | Agents and crystals for improving excretory potency of urinary bladder |
| JP4324266B2 (ja) * | 1999-02-26 | 2009-09-02 | キッセイ薬品工業株式会社 | α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
| US20010053780A1 (en) | 1999-04-30 | 2001-12-20 | Whitaker John S. | Daily treatment for erectile dysfunction using a PDE5 inhibitor |
| JP4014068B2 (ja) * | 1999-07-28 | 2007-11-28 | 芦森工業株式会社 | エアバッグ装置 |
| PE20011178A1 (es) * | 2000-04-07 | 2001-11-19 | Takeda Chemical Industries Ltd | Compuestos heterociclicos y su produccion |
| WO2001087298A1 (fr) * | 2000-05-15 | 2001-11-22 | Rohto Pharmaceutical Co., Ltd. | Preparation liquide a base d'eau |
| AR033855A1 (es) * | 2001-01-26 | 2004-01-07 | Schering Corp | Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes |
| JP2001288115A (ja) | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
| US7189412B2 (en) * | 2001-03-01 | 2007-03-13 | Aska Pharmaceutical Co., Ltd. | Fenofibrate-containing composition |
| US6786714B2 (en) * | 2001-04-12 | 2004-09-07 | James W. Haskew | Delivery system for liquid catalysts |
| GB0113843D0 (en) | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
| UA78854C2 (en) * | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
-
2003
- 2003-12-11 ME MEP-108/08A patent/MEP10808A/xx unknown
- 2003-12-11 KR KR1020057010977A patent/KR101072909B1/ko active IP Right Grant
- 2003-12-11 ES ES03780719.5T patent/ES2544560T3/es not_active Expired - Lifetime
- 2003-12-11 CN CN2007100840362A patent/CN101069685B/zh not_active Expired - Lifetime
- 2003-12-11 JP JP2004560618A patent/JP4633469B2/ja not_active Expired - Lifetime
- 2003-12-11 CA CA2507002A patent/CA2507002C/en not_active Expired - Lifetime
- 2003-12-11 BR BR0317349-6A patent/BR0317349A/pt not_active Application Discontinuation
- 2003-12-11 US US10/538,514 patent/US20060018959A1/en not_active Abandoned
- 2003-12-11 CN CNB2003801062486A patent/CN100339078C/zh not_active Ceased
- 2003-12-11 AU AU2003289320A patent/AU2003289320C1/en active Active
- 2003-12-11 MX MXPA05006513A patent/MXPA05006513A/es active IP Right Grant
- 2003-12-11 RS YU20050470A patent/RS58025B1/sr unknown
- 2003-12-11 NZ NZ540664A patent/NZ540664A/en not_active IP Right Cessation
- 2003-12-11 PL PL377495A patent/PL220457B1/pl unknown
- 2003-12-11 UA UAA200809667A patent/UA85359C2/ru unknown
- 2003-12-11 UA UAA200507046A patent/UA84694C2/ru unknown
- 2003-12-11 WO PCT/JP2003/015837 patent/WO2004054574A1/ja active Application Filing
- 2003-12-11 EP EP03780719.5A patent/EP1574215B1/en not_active Revoked
- 2003-12-11 EA EA200500985A patent/EA008196B1/ru unknown
- 2003-12-11 EP EP11007870A patent/EP2402010A1/en not_active Withdrawn
- 2003-12-11 ME MEP-2008-108A patent/ME00076B/me unknown
- 2003-12-11 KR KR1020107026925A patent/KR101077061B1/ko active IP Right Grant
- 2003-12-15 TW TW092135358A patent/TWI325318B/zh not_active IP Right Cessation
- 2003-12-15 TW TW098121810A patent/TWI382838B/zh not_active IP Right Cessation
-
2005
- 2005-06-06 ZA ZA200504613A patent/ZA200504613B/en unknown
- 2005-06-07 IL IL169040A patent/IL169040A/en active IP Right Grant
- 2005-06-14 HR HRP20050544AA patent/HRP20050544B1/hr not_active IP Right Cessation
- 2005-07-01 IS IS7929A patent/IS7929A/is unknown
- 2005-07-15 NO NO20053467A patent/NO20053467L/no not_active Application Discontinuation
-
2006
- 2006-05-08 HK HK06105339A patent/HK1085131A1/xx not_active IP Right Cessation
- 2006-05-08 HK HK08101016.0A patent/HK1107768A1/xx not_active IP Right Cessation
-
2011
- 2011-11-03 US US13/288,348 patent/US20120064154A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200504613B (en) | Solid drug for oral use | |
| JPWO2008129846A1 (ja) | 医薬組成物 | |
| JP4805234B2 (ja) | 経口固形医薬 | |
| US8603537B2 (en) | Prasugrel containing quickly released stable oral pharmaceutical compositions | |
| CA2621545A1 (en) | Ramipril formulation | |
| KR20180096530A (ko) | 이토프리드 염산염을 포함하는 속효성과 지속성을 갖는 약학적 제제 | |
| WO2008068778A2 (en) | Extended release pharmaceutical composition of pramipexole | |
| US20080089936A1 (en) | Prolonged release formulation of active principles having a ph-dependent solubility | |
| US20210369624A1 (en) | Solid oral dosage form having excellent dissolution properties | |
| NZ555003A (en) | Solid drug for oral use comprising indoline compound | |
| ES2868228T3 (es) | Formas de dosificación farmacéuticas que contienen 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio | |
| CN115804774B (zh) | 一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用 | |
| US20230092490A1 (en) | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof | |
| US10034855B2 (en) | Solid composition of pyrrole carboxamide | |
| JP2009209137A (ja) | 服用性が改善された錠剤 | |
| KR20240107122A (ko) | 우수한 용출성을 갖는 의약 조성물 |